00:15 , Mar 2, 2018 |  BC Innovations  |  Product R&D

Sigma for synapses

By focusing on synapse protection instead of aggregate formation, Cognition Therapeutics Inc. has identified a new target for Alzheimer’s disease that it believes can block β amyloid’s toxic effects more efficiently than the standard approaches....
20:01 , Nov 16, 2017 |  BC Innovations  |  Tools & Techniques

Yeast against aggregation

In drug discovery for neurodegenerative diseases, the emphasis is on finding better models of neuronal systems that recapitulate synapses, neuroinflammation and the pathological accumulation of toxic aggregates. Yumanity Therapeutics LLC and a handful of academic...
22:56 , Nov 14, 2017 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Cellular assays; binding assays; high throughput screening A high throughput, yeast-based method for measuring protein aggregate formation could help screen therapies that inhibit pathological protein aggregation. The method involves expressing fusions of aggregation-prone proteins...
17:17 , Nov 8, 2017 |  BC Extra  |  Preclinical News

Team identifies new role for SORL1 in Alzheimer's disease

In a paper published in The Journal of Experimental Medicine , researchers at Sanford Burnham Prebys Medical Discovery Institute and colleagues showed that sortilin-related receptor 1 (SORL1; gp250; LR11) attenuates beta amyloid-induced neurodegeneration, suggesting a...
20:58 , Jul 18, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) Cell culture and mouse studies suggest an allosteric modulator of the mGluR5 - PRNP interaction could help treat AD. In a transgenic mouse model of AD, oral 7.5 mg/kg daily doses...
21:14 , Feb 16, 2017 |  BC Innovations  |  Translation in Brief

A wrinkle in prion

A form of fatal encephalitis called variant Creutzfeldt-Jakob disease has been transmitted through blood transfusions at least four times in the U.K. because no test exists that can screen blood samples for the misfolded prion...
17:56 , Feb 15, 2017 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Diagnostic assays A blood-based assay for detecting abnormally folded PRNP could diagnose variant Creutzfeldt-Jakob disease before the onset of clinical symptoms. The assay involved capturing abnormally folded PRNP from blood or serum samples with...
14:18 , Dec 22, 2016 |  BC Innovations  |  Targets & Mechanisms

Opportunity Knocks

Despite its continued emphasis on tapping external innovation for new opportunities, industry is still leaving on the table scores of unexploited drug targets identified at universities, according to an analysis of BioCentury’s BCIQ: BioCentury Online...
07:00 , Jul 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: An undetermined target

Neurology INDICATION: Neurology Cell culture and mouse studies identified four aryl amide-based compounds that could help treat prion infections of the CNS. Chemical synthesis and testing in a prion-infected mouse neuronal cell line of aryl...
07:00 , Mar 17, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Prion protein 2 (dublet) (PRND)

Cancer INDICATION: Cancer Patient sample and mouse studies suggest inhibiting PRND could help treat cancer. In lung and colon cancer patients, PRND levels were higher in tumor vasculature than in normal adjacent tissue and vasculature....